• Tianjin TEDA Biomedical Engineering granted 4,000,000 H Shares to subsidiary director Li Wanchen on October 21, 2026, subject to acceptance.
• The award, valued at approximately HKD 700,000, vests in one tranche 12 months from the grant date.
• Vesting carries no performance targets or clawback mechanism.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin TEDA Biomedical Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261021-12378266), on October 21, 2026, and is solely responsible for the information contained therein.